JP Morgan Notebook Day Two: Lilly, Amgen, Shire, Bristol-Myers, Takeda And Drug Pricing
This article was originally published in Scrip
Executive Summary
Eli Lilly & Co. is in its second year of recovery following a rough period of drug patent expirations that hit the big pharma's revenue, because there were not enough new drug launches to make up for those losses, but CEO John Lechleiter says that's changing rapidly.